• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用另一个签名分析包分析突变特征。

Analysis of mutational signatures with yet another package for signature analysis.

机构信息

Computational Oncology, Molecular Diagnostics Program, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Germany.

Pattern Recognition and Digital Medicine, Heidelberg Institute of Stem Cell Technology and Experimental Medicine (HI-STEM), Im Neuenheimer Feld 280, Heidelberg, 69120, Germany.

出版信息

Genes Chromosomes Cancer. 2021 May;60(5):314-331. doi: 10.1002/gcc.22918. Epub 2020 Dec 31.

DOI:10.1002/gcc.22918
PMID:33222322
Abstract

Different mutational processes leave characteristic patterns of somatic mutations in the genome that can be identified as mutational signatures. Determining the contributions of mutational signatures to cancer genomes allows not only to reconstruct the etiology of somatic mutations, but can also be used for improved tumor classification and support therapeutic decisions. We here present the R package yet another package for signature analysis (YAPSA) to deconvolute the contributions of mutational signatures to tumor genomes. YAPSA provides in-built collections from the COSMIC and PCAWG SNV signature sets as well as the PCAWG Indel signatures and employs signature-specific cutoffs to increase sensitivity and specificity. Furthermore, YAPSA allows to determine 95% confidence intervals for signature exposures, to perform constrained stratified signature analyses to obtain enrichment and depletion patterns of the identified signatures and, when applied to whole exome sequencing data, to correct for the triplet content of individual target capture kits. With this functionality, YAPSA has proved to be a valuable tool for analysis of mutational signatures in molecular tumor boards in a precision oncology context. YAPSA is available at R/Bioconductor (http://bioconductor.org/packages/3.12/bioc/html/YAPSA.html).

摘要

不同的突变过程会在基因组中留下特征性的体细胞突变模式,这些模式可以被识别为突变特征。确定突变特征对癌症基因组的贡献不仅可以重建体细胞突变的病因,还可以用于改进肿瘤分类和支持治疗决策。我们在这里介绍 R 包 yet another package for signature analysis (YAPSA),用于解析突变特征对肿瘤基因组的贡献。YAPSA 提供了来自 COSMIC 和 PCAWG SNV 特征集以及 PCAWG Indel 特征的内置集合,并采用特征特异性截止值来提高敏感性和特异性。此外,YAPSA 允许确定特征暴露的 95%置信区间,执行受限分层特征分析以获得已识别特征的富集和耗尽模式,并且当应用于全外显子组测序数据时,可以校正个体靶标捕获试剂盒的三联体含量。通过这些功能,YAPSA 已被证明是在精准肿瘤学背景下进行分子肿瘤委员会突变特征分析的有价值的工具。YAPSA 可在 R/Bioconductor(http://bioconductor.org/packages/3.12/bioc/html/YAPSA.html)上获得。

相似文献

1
Analysis of mutational signatures with yet another package for signature analysis.使用另一个签名分析包分析突变特征。
Genes Chromosomes Cancer. 2021 May;60(5):314-331. doi: 10.1002/gcc.22918. Epub 2020 Dec 31.
2
MutationalPatterns: the one stop shop for the analysis of mutational processes.突变模式:分析突变过程的一站式商店。
BMC Genomics. 2022 Feb 15;23(1):134. doi: 10.1186/s12864-022-08357-3.
3
Mutational Signatures in Cancer (MuSiCa): a web application to implement mutational signatures analysis in cancer samples.癌症突变特征(MuSiCa):一个用于在癌症样本中实施突变特征分析的网络应用程序。
BMC Bioinformatics. 2018 Jun 14;19(1):224. doi: 10.1186/s12859-018-2234-y.
4
Mutational signatures of colorectal cancers according to distinct computational workflows.根据不同的计算工作流程,结直肠癌的突变特征。
Brief Bioinform. 2024 May 23;25(4). doi: 10.1093/bib/bbae249.
5
Relating mutational signature exposures to clinical data in cancers via signeR 2.0.通过 signeR 2.0 将突变特征暴露与癌症临床数据相关联。
BMC Bioinformatics. 2023 Nov 22;24(1):439. doi: 10.1186/s12859-023-05550-3.
6
decompTumor2Sig: identification of mutational signatures active in individual tumors.decompTumor2Sig:鉴定个体肿瘤中活跃的突变特征。
BMC Bioinformatics. 2019 Apr 18;20(Suppl 4):152. doi: 10.1186/s12859-019-2688-6.
7
The repertoire of mutational signatures in human cancer.人类癌症中的突变特征谱。
Nature. 2020 Feb;578(7793):94-101. doi: 10.1038/s41586-020-1943-3. Epub 2020 Feb 5.
8
SigsPack, a package for cancer mutational signatures.SigsPack,用于癌症突变特征的软件包。
BMC Bioinformatics. 2019 Sep 2;20(1):450. doi: 10.1186/s12859-019-3043-7.
9
CANCERSIGN: a user-friendly and robust tool for identification and classification of mutational signatures and patterns in cancer genomes.CANCERSIGN:一款用户友好且强大的工具,用于鉴定和分类癌症基因组中的突变特征和模式。
Sci Rep. 2020 Jan 28;10(1):1286. doi: 10.1038/s41598-020-58107-2.
10
FIREVAT: finding reliable variants without artifacts in human cancer samples using etiologically relevant mutational signatures.FIREVAT:使用与病因相关的突变特征在人类癌症样本中无伪影地发现可靠变异。
Genome Med. 2019 Dec 17;11(1):81. doi: 10.1186/s13073-019-0695-x.

引用本文的文献

1
Predicting resistance to chemotherapy using chromosomal instability signatures.利用染色体不稳定性特征预测化疗耐药性。
Nat Genet. 2025 Jun 23. doi: 10.1038/s41588-025-02233-y.
2
Small intestinal neuroendocrine tumors lack early genomic drivers, acquire DNA repair defects and harbor hallmarks of low REST expression.小肠神经内分泌肿瘤缺乏早期基因组驱动因素,存在DNA修复缺陷,并具有低REST表达的特征。
Sci Rep. 2025 May 23;15(1):17969. doi: 10.1038/s41598-025-01912-4.
3
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics.
同源重组缺陷(HRD)检测概况:常规诊断的临床应用与技术验证
Biomark Res. 2025 Feb 21;13(1):31. doi: 10.1186/s40364-025-00740-y.
4
Benchmarking 13 tools for mutational signature attribution, including a new and improved algorithm.对13种用于突变特征归因的工具进行基准测试,包括一种新的改进算法。
Brief Bioinform. 2024 Nov 22;26(1). doi: 10.1093/bib/bbaf042.
5
Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology.分子诊断与靶向癌症治疗对患者预后的影响(MODIFY):精准肿瘤学实施情况的回顾性研究
Mol Oncol. 2025 May;19(5):1508-1516. doi: 10.1002/1878-0261.13785. Epub 2024 Dec 11.
6
Temporal evolution and inter-patient heterogeneity in primary and recurrent head and neck squamous cell carcinoma.原发性和复发性头颈部鳞状细胞癌的时间演变及患者间异质性
BJC Rep. 2024 Aug 29;2(1):62. doi: 10.1038/s44276-024-00091-5.
7
A comprehensive comparison of tools for fitting mutational signatures.全面比较用于拟合突变特征的工具。
Nat Commun. 2024 Nov 2;15(1):9467. doi: 10.1038/s41467-024-53711-6.
8
A Subset of Microsatellite Unstable Cancer Genomes Prone to Short Insertions over Deletions Is Associated with Elevated Anticancer Immunity.微卫星不稳定癌症基因组的一个子集易于发生短插入缺失,与抗肿瘤免疫增强有关。
Genes (Basel). 2024 Jun 12;15(6):770. doi: 10.3390/genes15060770.
9
Genomic characterization and risk stratification of esophageal squamous dysplasia.食管鳞状上皮发育异常的基因组特征及风险分层
Med Rev (2021). 2024 May 15;4(3):244-256. doi: 10.1515/mr-2024-0008. eCollection 2024 Jun.
10
Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.分子制导疗法治疗复发和难治性儿童癌症患者:Beat 儿童癌症研究联盟试验。
Genome Med. 2024 Feb 12;16(1):28. doi: 10.1186/s13073-024-01297-5.